Amgen third-quarter revenue falls 3%, biosimilar sales rise
October 29, 2019 at 16:12 PM EDT
Amgen Inc on Tuesday said competition for older off-patent drugs sent third-quarter revenue down 3%, but share repurchases and biosimilar sales helped it achieve higher-than-expected profit, and the company raised its full-year outlook.